BC Week In Review | Jun 15, 2009
Clinical News

Alequel: Phase IIb data

In a double-blind Phase IIb trial in 43 patients, Alequel met the primary endpoint of remission rate (CDAI score <=150) at 2 consecutive time points 3 weeks apart. Between weeks 6-9, 43% patients receiving Alequel...
BioCentury | Feb 18, 2008
Strategy

Functional GI compounds

Functional GI compounds Constipation Company Product Description Target Indication Status Progenics (NASDAQ:PGNX)/ Methylnaltrexone Peripheral mu opioid Mu opioid receptor Opioid-induced Apr 30 Wyeth (NYSE:WYE) (MNTX) receptor antagonist constipation (OIC) PDUFA Adolor (NASDAQ:ADLR)/ GlaxoSmithKline(LSE:GSK; NYSE:GSK) Entereg...
BC Week In Review | May 28, 2007
Clinical News

Alequel: Final Phase II data

In a pair of double-blind, Phase II trials in a total of 49 patients, 39% of Alequel patients had a clinical response compared with 22% of placebo patients, a difference that was not statistically significant....
BC Extra | Dec 16, 2006
Financial News

Enzo raises $46 million

ENZ raised $46 million through a registered direct offering of 3.3 million shares at $14, which is an 8% discount to ENZ's close of $15.30 on Thursday. Lazard was placement agent. ENZ's Alequel is in...
BC Week In Review | Oct 4, 2004
Clinical News

Alequel: Phase II data

In a double-blind, placebo-controlled Phase II trial in 26 evaluable patients, 67% of those given Alequel had a clinical response compared to 43% of patients in the placebo group. Also, 58% of Alequel patients achieved...
BioCentury | Oct 4, 2004
Finance

The brave Atlantic alliance

While European investors continue to put their money into the U.S., a change in the Paris Stock Exchange rules is making it easier for U.S. investors to hunt for bargains in Europe. NicOx (NM:Nicox) last...
BC Extra | Sep 29, 2004
Clinical News

Enzo Phase II Crohn's data

ENZ said its Alequel met the endpoints of clinical response and clinical remission in a Phase II trial in Crohn's disease. In the double-blind trial, data from 26 evaluable patients showed that 67% of those...
BioCentury | Mar 29, 2004
Product Development

Crohn's cronies

Crohn's cronies Company Product Description Status Partner Johnson & Johnson Remicade Antitumor necrosis alpha chimeric Mab Mkt Schering-Plough Abbott Humira Human MAb against TNF alpha Ph III; marketed for rheumatoid arthritis (RA) Biogen Idec Antegren...
BC Week In Review | Mar 15, 2004
Clinical News

Alequel: Phase II

Interim results from an ongoing, double-blind, placebo-controlled, Israeli Phase II study showed 5 of 7 patients receiving Alequel achieved clinical remission compared to 3 of 12 placebo patients. Clinical remission was defined as a CDAI...
BC Extra | Mar 11, 2004
Clinical News

Enzo Alequel Phase II data

ENZ said that in an ongoing, double-blind Israeli Phase II study in Crohn's disease patients, 5 of 7 patients receiving its Alequel achieved clinical remission compared to 3 of 12 placebo patients. Clinical remission was...
Items per page:
1 - 10 of 10